Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1

Active, not recruiting

Conditions: Bladder Cancer
Metastatic Bladder Cancer
Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2016-12-12

Last Posted Date: 2025-01-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT02989584

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States

and more 8 locations

PEACE: Comparing Chronic Pain Treatment Options

Not Applicable

Active, not recruiting

Conditions: Pain Management
Chronic Pain
Fibromyalgia
Musculoskeletal Pain

Interventions: Procedure: Electro-Acupuncture (EA)
Procedure: Battle Field Acupuncture (BFA)
Device: Wait List Control (WLC)

First Posted Date: 2016-12-01

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 360

Registration Number: NCT02979574

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

and more 4 locations

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Drug: Ruxolitinib

First Posted Date: 2016-11-28

Last Posted Date: 2025-05-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT02974647

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Northwestern Medicine (Data collection and specimen analysis), Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 7 locations

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Early Phase 1

Terminated

Conditions: Follicular Lymphoma, Grade 2
Follicular Lymphoma, Grade 1
Follicular Lymphoma Grade IIIa
Follicular Lymphoma

Interventions: Drug: Ibrutinib

First Posted Date: 2016-11-17

Last Posted Date: 2025-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT02966730

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 6 locations

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Phase 1

Recruiting

Conditions: Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: durvalumab
Drug: carboplatin AUC 2/paclitaxel
Radiation: External beam radiation (EBRT)
Procedure: esophagogastrectomy
Drug: Tremelimumab

First Posted Date: 2016-11-11

Last Posted Date: 2024-10-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 79

Registration Number: NCT02962063

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 4 locations

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: pembrolizumab
Drug: trastuzumab
Drug: capecitabine
Drug: cisplatin
Drug: Oxaliplatin
Drug: 5-Fluorouracil

First Posted Date: 2016-11-03

Last Posted Date: 2023-03-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT02954536

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

Interest and Impact of Skin Cancer Genetic Testing

Completed

Conditions: Non-melanoma Skin Cancer (NMSC)

Interventions: Genetic: MC1R genotyping
Behavioral: MC1R Testing Website
Behavioral: Baseline Survey

First Posted Date: 2016-10-21

Last Posted Date: 2023-01-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 53

Registration Number: NCT02941900

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

High Dose Carfilzomib for Newly Diagnosed Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-10-18

Last Posted Date: 2024-10-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT02937571

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 2 locations

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Phase 1

Active, not recruiting

Conditions: Central Nervous System Tumor
Solid Tumor
Leukemia
Lymphoma

Interventions: Drug: Neratinib

First Posted Date: 2016-10-13

Last Posted Date: 2024-12-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT02932280

Locations: 🇺🇸
University of Texas, San Antonio, Texas, United States
🇺🇸
Huntsman Cancer Institue, Salt Lake City, Utah, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 6 locations

Adaptation of Skills Training Manuals for Patients Receiving Hematopoietic Stem Cell Transplantation and Their Caregivers

Active, not recruiting

Conditions: Post Hematopoietic Stem Cell Transplantation

Interventions: Behavioral: semi-structured interviews

First Posted Date: 2016-10-10

Last Posted Date: 2024-08-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT02928185

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy